CML: Langzeitresultate Zum Imatinib-Stopp

Im Focus Onkologie
doi 10.1007/s15015-017-3672-5
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Verschiedene Wege Zum Therapiefreien Leben Mit CML

Im Focus Onkologie
2017English

MATE1 Regulates Cellular Uptake and Sensitivity to Imatinib in CML Patients

Blood Cancer Journal
OncologyHematology
2016English

Efficacy and Safety of Imatinib in Paediatric CML – A Single Centre Study

In Vivo
BiochemistryMedicineGeneticsPharmacologyMolecular Biology
2019English

Downregulation of Γ-Catenin Inhibits CML Cell Growth and Potentiates the Response of CML Cells to Imatinib Through Β-Catenin Inhibition

International Journal of Molecular Medicine
MedicineGenetics
2012English

Long-Term Survival With CML With Imatinib or Transplantation as First-Line Treatment: Comparison of Outcomes From CML Studies IIIA and IV

Cellular Therapy and Transplantation
TransplantationMolecular Medicine
2017English

Duplication of Isoderivative Ph Chromosome With Tp53 Deletion in a Case of Imatinib Resistant CML

International Journal of Human Genetics
Genetics
2019English

Lonafarnib Reduces the Resistance of Primitive Quiescent CML Cells to Imatinib Mesylate in Vitro

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2005English

CXCR4 Up-Regulation by Imatinib Induces Chronic Myelogenous Leukemia (CML) Cell Migration to Bone Marrow Stroma and Promotes Survival of Quiescent CML Cells

Molecular Cancer Therapeutics
Cancer ResearchOncology
2008English

Prognostic Factors for Outcomes in Allogeneic Transplantation for CML in the Imatinib Era: A CIBMTR Analysis

Bone Marrow Transplantation
TransplantationHematology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy